 "Cipla, Cipla logo, Cipla headquarters")
Cipla, which has a strong portfolio of Covid-19 drugs, says it is now open to forge a partnership to distribute Covid vaccines in India.
“We are open to having a vaccine partnership. A company that will be able to do vaccine distribution successfully in India will have significant distribution muscle – like large warehouses, cold chain capabilities, footprint throughout India. We fit the bill well. We are open to it, but as of now nothing to report,” said Kedar Upadhye, global CFO of Cipla. Cipla does not want to get into vaccine manufacturing. It is augmenting its Covid-19 therapy portfolio too.
